1.17

6.40% -0.08

Pre-market: 1.21 0.04 +3.42%

Rapt Therapeutics Inc (RAPT)

Overview News Price History Option Chain Financials Discussions Forecast

Rapt Therapeutics Inc stock is traded at $1.17, with a volume of 429.62K. It is down -6.40% in the last 24 hours and down -1.68% over the past month. RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Previous Close:

$1.25

Open:

$1.25

24h Volume:

429.62K

Relative Volume:

0.14

Market Cap:

$154.45M

Revenue:

$3.25M

Net Income/Loss:

$-116.80M

P/E Ratio:

-0.3836

EPS:

-3.05

Net Cash Flow:

$-98.17M

1W Performance:

+4.46%

1M Performance:

-1.68%

6M Performance:

-40.00%

1Y Performance:

-86.36%

1-Day Range:

$1.16

$1.265

1-Week Range:

$1.04

$1.30

52-Week Range:

$0.7893

$9.6536

Rapt Therapeutics Inc Stock (RAPT) Company Profile

Name

Rapt Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (679)

Phone

(650) 489-9000

Address

561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

RAPT's Discussions on Twitter

Compare RAPT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RAPT Rapt Therapeutics Inc	1.17	154.45M	3.25M	-116.80M	-98.17M	-3.05
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-26-24	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-13-24	Downgrade	Stifel	Buy → Hold
Nov-11-24	Downgrade	JP Morgan	Neutral → Underweight
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
May-14-24	Downgrade	Wolfe Research	Outperform → Peer Perform
May-10-24	Downgrade	Barclays	Overweight → Equal Weight
May-10-24	Downgrade	Guggenheim	Buy → Neutral
Feb-22-24	Downgrade	UBS	Buy → Neutral
Feb-21-24	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-21-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-21-24	Downgrade	Leerink Partners	Outperform → Market Perform
Feb-20-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-16-24	Initiated	Evercore ISI	Outperform
Feb-15-24	Initiated	Wolfe Research	Outperform
Sep-14-23	Initiated	Berenberg	Buy
Aug-09-23	Initiated	Stifel	Buy
Jun-15-23	Initiated	Barclays	Overweight
Jan-04-23	Initiated	Guggenheim	Buy
Dec-01-22	Initiated	Goldman	Buy
Sep-21-22	Initiated	CapitalOne	Overweight
May-24-22	Resumed	Cantor Fitzgerald	Overweight
Dec-09-21	Initiated	JP Morgan	Overweight
Aug-12-21	Initiated	SVB Leerink	Outperform
Jun-21-21	Initiated	Piper Sandler	Overweight
Jun-01-20	Initiated	H.C. Wainwright	Buy
May-19-20	Initiated	Cantor Fitzgerald	Overweight
Apr-13-20	Initiated	ROTH Capital	Buy
Nov-25-19	Initiated	BMO Capital Markets	Outperform
Nov-25-19	Initiated	UBS	Buy
Nov-25-19	Initiated	Wells Fargo	Outperform

View All

Rapt Therapeutics Inc Stock (RAPT) Latest News

Mar 13, 2025

Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst - Defense World

Mar 13, 2025

Mar 12, 2025

Equities Analysts Set Expectations for RAPT FY2026 Earnings - Defense World

Mar 12, 2025

Mar 11, 2025

RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright - Defense World

Mar 11, 2025

Mar 10, 2025

RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss - TipRanks

Mar 10, 2025

Mar 07, 2025

RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 07, 2025

Double Feature: RAPT Therapeutics Takes Center Stage at Major Healthcare Investment Forums - StockTitan

Mar 07, 2025

Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating - TipRanks

Mar 07, 2025

Mar 06, 2025

RAPT Therapeutics Focuses on RPT904 Development in 2025 - TipRanks

Mar 06, 2025

RAPT Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025

RAPT THERAPEUTICS Earnings Results: $RAPT Reports Quarterly Earnings - Nasdaq

Mar 06, 2025

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 06, 2025

RAPT Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 06, 2025

Rapt Therapeutics reports Q4 EPS ($1.14), consensus (36c) - TipRanks

Mar 06, 2025

Can RAPT's $231M War Chest and New Food Allergy Drug Transform Its Future? - StockTitan

Mar 06, 2025

Mar 03, 2025

RAPT Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView

Mar 03, 2025

Feb 27, 2025

RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday - Defense World

Feb 27, 2025

Feb 23, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts - Defense World

Feb 23, 2025

Feb 16, 2025

Still Cautious Over RAPT Therapeutics’ Fresh Start With RPT904 (NASDAQ:RAPT) - Seeking Alpha

Feb 16, 2025